- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-239/20: Judgment of the General Court of 10 November 2021 — Stada Arzneimittel v EUIPO — Pfizer (RUXXIMLA) (EU trade mark — Opposition proceedings — Application for the EU word mark RUXXIMLA — Earlier EU word mark RUXIMERA — Relative ground for refusal — Likelihood of confusion — Similarity of the signs — Article 8(1)(b) of Regulation (EU) 2017/1001)
ECLI:EU:UNKNOWN:62020TA0239
62020TA0239
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 2/30
(Case T-239/20) (*)
(EU trade mark - Opposition proceedings - Application for the EU word mark RUXXIMLA - Earlier EU word mark RUXIMERA - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation (EU) 2017/1001)
(2022/C 2/39)
Language of the case: English
Parties
Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
Defendant: European Union Intellectual Property Office (represented by: D. Gája, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard and J. Fuhrmann, lawyers)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 (Case R 1879/2019-4), relating to opposition proceedings between Pfizer and Stada Arzneimittel.
Operative part of the judgment
The Court:
1.Dismisses the action;
2.Orders Stada Arzneimittel AG to pay the costs.
(*)
Language of the case: English
ECLI:EU:C:2022:140